Clinical Trial Update: Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring bladder-preserving therapy with sacituzumab govitecan plus zimberelimab for muscle-invasive bladder cancer; the study is not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Bladder Urothelial Carcinoma
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Bladder Cancer, Bladder Urothelial Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING